financetom
Business
financetom
/
Business
/
PRESS DIGEST- Financial Times - February 20
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
PRESS DIGEST- Financial Times - February 20
Feb 19, 2025 5:59 PM

Feb 20 (Reuters) - The following are the top stories in

the Financial Times. Reuters has not verified these stories and

does not vouch for their accuracy.

Headlines

- Wood Group's CFO steps down after inaccurate claims about

qualifications

-KKR submits 4 billion pounds bid to take majority stake in

Thames Water

- Owners of UK energy networks made billions in excess

returns, says watchdog

- Melrose founders' Rosebank in talks to buy U.S.

engineering group for $2 billion

Overview

- The chief financial officer at embattled engineer John

Wood Group has stepped down with immediate effect after

he admitted to misstating his professional qualifications.

- KKR has submitted a preliminary 4 billion pounds

($5.04 billion) equity bid to take a majority stake in Thames

Water, as the U.S. private equity firm looks to position itself

as the most credible potential owner of the debt-laden water

provider.

- The owners of Britain's gas and electricity networks have

made billions of pounds in excess returns as a result of a

"policy failure" by regulator Ofgem, according to consumer

watchdog Citizens Advice.

- Rosebank Industries, the listed private equity

vehicle established by former founders of FTSE listed British

turnaround specialist Melrose, has said it is in discussions

with U.S.-based electrical engineering group Electrical

Components International over a possible acquisition.

($1 = 0.7943 pounds)

(Reporting by Surbhi Misra in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tamarack Valley Energy Declares Monthly Dividend
Tamarack Valley Energy Declares Monthly Dividend
Dec 16, 2024
09:15 AM EST, 12/16/2024 (MT Newswires) -- Tamarack Valley Energy ( TNEYF ) on Monday declared a monthly cash dividend on its common shares of $0.01275 per share, same as the prior month. The dividend will be payable on Jan. 15 to shareholders of record at the close of business on Dec. 30. Shares of the company closed down $0.03...
Clarivate Approves Up to $500 Million Share Buyback Plan
Clarivate Approves Up to $500 Million Share Buyback Plan
Dec 16, 2024
09:13 AM EST, 12/16/2024 (MT Newswires) -- Clarivate ( CLVT ) said Monday that its board has approved an up to $500 million share buyback plan to replace the current program. The company said the new plan will be valid from Jan. 1, 2025, to Dec. 31, 2026. Clarivate ( CLVT ) also said it prepaid $75 million of term-loan...
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- GSK (GSK) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the approval of its experimental drug, Jemperli, in combination with chemotherapy, as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. The company said the...
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Dec 16, 2024
09:20 AM EST, 12/16/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday that initial data from its ongoing long-term study of its experimental therapy nomlabofusp in patients with Friedreich's ataxia leaned toward improved clinical outcomes at day 90. The company said patients treated with daily injections of nomlabofusp saw tissue frataxin levels increase, supporting the drug's potential in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved